Exploring Qualigen Therapeutics, Inc. (QLGN) Investor Profile: Who’s Buying and Why?

You're looking at Qualigen Therapeutics, Inc. (QLGN) and trying to figure out if the recent investor profile shift is a legitimate pivot or just a speculative trade. The direct takeaway is this: the company you knew is gone, replaced by a new entity, AIxCrypto Holdings, Inc., and the investor base has been fundamentally remade by a controlling block, so your analysis needs a complete reset. Honestly, how do you value a biotech with trailing twelve-month earnings of negative $7.0 million as of June 30, 2025, that suddenly transforms into an AI and Web3 play? The answer is you don't use the old model, especially when the institutional ownership, which was a tiny 3.18% of the stock, is now overshadowed by a single, massive new shareholder.

Here's the quick math: Faraday Future Intelligent Electric Inc. just became the majority and controlling shareholder with an estimated 55% direct equity ownership-jumping to approximately 63% when you include affiliates-effectively turning a small, publicly traded entity with a market cap of around $5.31 million into a controlled subsidiary. This isn't a minor portfolio adjustment; it's a defintely material change in governance and strategy, backed by the issuance of over 337,432 common shares and 39,943 Series B convertible preferred shares. Who is buying now, and what are they really buying? The smart money is following the new control dynamic, not the old biotech pipeline, and the real question is how the remaining minority float will perform under this new, concentrated ownership structure and a radically different business model.

Who Invests in Qualigen Therapeutics, Inc. (QLGN) and Why?

You're looking at Qualigen Therapeutics, Inc. (QLGN), and the investor profile is anything but typical. Forget the old biotech story; the real action in 2025 is the massive strategic pivot to decentralized AI and Web3 technology, which is what's driving the capital. This shift has fundamentally split the investor base into a new, dominant strategic owner and a small, highly volatile mix of institutional and retail players.

The clear takeaway is this: the investment thesis for QLGN is no longer about drug pipelines. It's a bet on the success of the new business model, CXC10, backed by a major corporate entity. If you're buying now, you're buying the volatility and the potential for a massive growth re-rating, not a steady-state value play. The forecasted annual Earnings Before Interest and Taxes (EBIT) for 2025 is still a loss of around -$31 million, so this is defintely a high-risk, high-reward situation.

Key Investor Types: A Strategic Majority Emerges

The ownership structure of Qualigen Therapeutics, Inc. has been dramatically re-written by a single event in 2025: the strategic investment by Faraday Future Intelligent Electric Inc. (FFAI). This transaction created a new, controlling class of investor, sidelining the traditional mix.

• Controlling Strategic Investor: Faraday Future and its affiliates now dominate the cap table. Following a $41 million Private Investment in Public Equity (PIPE) transaction, Faraday Future holds approximately 55% direct equity ownership. This is a controlling stake, not a passive one.
• Affiliated Insider Capital: Adding in the $4 million personal investment from Faraday Future's founder, YT Jia, the combined control by the strategic partner and its affiliates is over 62% of the outstanding shares. This is a massive concentration of power and capital, signaling a long-term commitment to the pivot.
• Institutional Investors: Traditional institutional ownership remains small, hovering between 0.72% and 3.18% of the stock. These are typically index funds and quantitative (quant) hedge funds. For example, as of the Q3 2025 filings, BlackRock, Inc. held a small position of just 501 shares, and Cubist Systematic Strategies, LLC added 27,882 shares.
• Retail and Short-Term Traders: This group is the most reactive to the news cycle. They are the ones driving the massive short-term price swings-like the 211.97% stock surge seen following the initial news of the strategic shift.

Here's the quick math on the institutional side: the total institutional shares held were around 32,667 as of September 30, 2025, which is tiny in the grand scheme compared to the controlling stake.

Investment Motivations: The Web3 Growth Bet

The motivation for investing in Qualigen Therapeutics, Inc. has completely changed. Investors are no longer attracted by the original biotech pipeline; they are chasing the potential of the new business. The Q2 2025 earnings reported a loss of -$1.7 million, which tells you the legacy business wasn't the draw.

• Growth Prospects in Web3: The primary driver is the company's pivot to the crypto and Web3 domains, with the planned rebrand to CXC10. This is a pure growth play, betting that the new venture can capitalize on the burgeoning digital economy.
• Strategic Cash Infusion: The $41 million cash injection from Faraday Future provides the necessary liquidity and runway to execute the new strategy, which is a massive de-risking factor for a company that had been facing financial constraints.
• High Volatility and Momentum: For short-term traders, the stock's extreme volatility is the motivation. The stock price can swing wildly, creating opportunities for quick gains. For instance, the stock was trading up by 155.28% on news of the pivot in September 2025.

The strategic move also includes a treasury strategy focused on the top 10 crypto assets, which is a clear signal of the new, aggressive digital finance focus. You can read more about the long-term vision here: Mission Statement, Vision, & Core Values of Qualigen Therapeutics, Inc. (QLGN).

Investment Strategies: Speculation and Control

The investment strategies for QLGN are now polarized between the controlling entity and the public float.

• Long-Term Strategic Holding: Faraday Future and its founder are executing a long-term strategy. Their 62%+ stake is a locked-in position, aiming to maximize returns by transforming the company into a Web3 leader. YT Jia's personal shares, for example, have a two-year lockup, which is a classic sign of a commitment to a multi-year turnaround.
• Short-Term Momentum Trading: Retail and certain hedge funds employ short-term trading strategies. They are playing the news and the volatility, looking for quick profits from the massive price swings. This is pure speculation on the market's reaction to the pivot, not on fundamentals.
• Arbitrage and Quantitative Strategies: The small institutional holders, including quant funds, often engage in arbitrage or other systematic strategies (like those used by Cubist Systematic Strategies, LLC) designed to profit from the stock's high volatility and the corporate actions surrounding the rebranding and strategic change.

What this estimate hides is the true value of the new Web3 assets, which are not yet fully reflected in the stock price of $2.73 per share as of mid-November 2025. The market is still trying to price a biotech company that is rapidly becoming a crypto/AI venture, which is why you see such dramatic, speculative movements.

Institutional Ownership and Major Shareholders of Qualigen Therapeutics, Inc. (QLGN)

You need to understand the investor profile of Qualigen Therapeutics, Inc. (QLGN), but the picture has fundamentally changed in late 2025. The core takeaway is that the company's ownership structure is no longer defined by a diverse set of mutual funds and ETFs; it is now controlled by a single, strategic entity, Faraday Future Intelligent Electric Inc. (FFAI).

The New Controlling Investor: Faraday Future

The investor landscape for Qualigen Therapeutics, Inc. (QLGN) was completely reshaped in the latter half of the 2025 fiscal year. Following a $41 million Private Investment in Public Equity (PIPE) financing that closed on September 30, 2025, Faraday Future Intelligent Electric Inc. (FFAI) became the new majority and controlling shareholder. This move is the single most important factor in the company's investor profile right now.

Here's the quick math on the new control structure:

• Faraday Future Intelligent Electric Inc. (FFAI) holds an estimated 55% direct equity ownership.
• Total ownership, including affiliated stockholders like YT Jia and Jerry Wang, is approximately 63%.

This is a major, decisive block of ownership. The company is defintely no longer a biotechnology play; it's an AI $\times$ Web3 venture.

Top Institutional Investors (Pre-Acquisition Snapshot)

Before the Faraday Future control shift, Qualigen Therapeutics, Inc. (QLGN) was a micro-cap stock with relatively low interest from traditional institutional investors. As of the Q3 2025 filings (September 30, 2025), the total institutional ownership, excluding the new controlling block, stood at around 1.93% of outstanding shares. This small group of institutions held a total of 32,667 shares.

The largest of these non-controlling institutional holders, based on Q3 2025 data, were primarily quantitative and index-tracking funds:

What this table hides is that most of the traditional institutional money was already on the sidelines, or exiting, before the strategic pivot.

Changes in Ownership: The Strategic Pivot

The recent changes in ownership are less about minor portfolio adjustments and more about a wholesale corporate transformation. While some smaller institutions like Cubist Systematic Strategies, LLC added 27,882 shares in Q3 2025, the overwhelming change is the entry of Faraday Future and its affiliates.

• Inflow: The $41 million PIPE financing from Faraday Future and its partners is the primary inflow of institutional capital in 2025.
• Outflow/Stagnation: For the rest of the institutional base, Q3 2025 saw a mixed bag: 6 institutions increased their positions, but 5 decreased, and 6 held steady. This activity is typical for a company facing significant uncertainty, but it is dwarfed by the new controlling stake.

The shift is from a fragmented ownership base to a highly concentrated one, signaling a clear, new direction for the company. To get the full picture of this evolution, you can review the company's past and future strategy here: Qualigen Therapeutics, Inc. (QLGN): History, Ownership, Mission, How It Works & Makes Money.

Impact of Institutional Investors on Strategy and Stock

In the case of Qualigen Therapeutics, Inc. (QLGN), the impact of the new institutional owner, Faraday Future, is absolute. They didn't just buy a stake; they bought control and dictated a complete change in business model and corporate identity.

This controlling interest means:

• Strategic Overhaul: The company is abandoning its focus on oncology and immunology therapies to become a Web3-driven decentralized AI technology platform, rebranding as AIxCrypto Holdings, Inc. (AIXC) on November 20, 2025.
• Governance Control: Faraday Future will designate the majority of the reconstituted Board of Directors, giving them full control over all future corporate decisions.
• Stock Volatility: The stock price is now tied to the success of the new AI $\times$ Web3 strategy, not the former biotech pipeline, introducing a new risk profile.

The pre-existing, non-controlling institutional investors now have very little direct influence on strategy; their main decision is whether to hold their positions for the new AIxCrypto Holdings, Inc. venture or sell. The new majority shareholder has set the course, and the rest of the market must react to it.

Next Step: Review the November 20, 2025, Nasdaq ceremony details to understand the AIxCrypto Holdings, Inc. three-year development roadmap.

Key Investors and Their Impact on Qualigen Therapeutics, Inc. (QLGN)

The investor profile for Qualigen Therapeutics, Inc. (QLGN) has undergone a radical, near-total transformation in late 2025, so you need to throw out the old playbook. The story isn't about small institutional shifts anymore; it's about a complete change of control and strategy, driven by one dominant new player: Faraday Future Intelligent Electric Inc.

This massive pivot from a traditional biotechnology focus to a Web3-driven decentralized artificial intelligence (AI) platform is a direct result of a new majority owner. This isn't just a simple investment; it's a strategic takeover that fundamentally redefines the company's future, its risk profile, and its entire investor base.

Faraday Future: The New Majority and Controlling Shareholder

The most critical development for Qualigen Therapeutics, Inc. investors is the emergence of Faraday Future Intelligent Electric Inc. as the new majority and controlling shareholder. This move was cemented following the certified stockholder vote on November 16, 2025, which approved the company's strategic transformation.

Here's the quick math on their influence:

• Direct Equity Ownership: Faraday Future is expected to hold an estimated 55% of the company's direct equity.
• Total Control Stake: Including affiliated stockholders, such as YT Jia and Jerry Wang, the total controlling stake rises to approximately 63%.
• Governance Impact: Faraday Future will designate the majority of the reconstituted Board of Directors, giving them full operational and strategic control.

This is a clear change of control (a Schedule 13D event) that immediately alters the power structure. The original biotech mission is out; the new AI × Web3 focus is in. You can read more about the new direction here: Mission Statement, Vision, & Core Values of Qualigen Therapeutics, Inc. (QLGN).

The Investment That Forced the Pivot

The control shift was enabled by a significant capital injection. Faraday Future led a Private Investment in Public Equity (PIPE) financing, bringing in a huge $41M to the former biotech firm. This capital was crucial, especially considering the company's financial position, which reported trailing 12-month earnings of -$7.0M ending June 30, 2025, and a projected annual Earnings Before Interest and Taxes (EBIT) forecast of -$31MM for the 2025 fiscal year. The new capital provides the runway for the dramatic strategic shift.

To finalize the control transfer and the strategic pivot to AIxCrypto Holdings, Inc., shareholders approved the issuance of 337,432 common shares and 39,943 Series B convertible preferred shares. This is the mechanism that legally transferred control and enabled the company to exceed Nasdaq's 19.99% issuance threshold for a change of control.

Institutional Investors: The Legacy Holders

While the focus is now on Faraday Future, a small group of institutional investors still holds a minority stake. Institutional investors collectively owned about 3.18% of Qualigen Therapeutics, Inc. stock before the recent changes. Their influence is now minimal compared to the new majority owner.

The institutional investor landscape for QLGN in 2025 was a mixed bag, showing little consensus on the stock's direction before the pivot. Here's a look at some of the notable institutional holders and their Q3 2025 activity:

To be fair, these institutional moves are small potatoes now. The buying and selling by firms like Cubist or the exit by Coastal Bridge Advisors is noise compared to the $41M investment and 55% direct ownership stake taken by Faraday Future. The new investor profile is defintely a one-name show, and your investment decisions must reflect the new, technology-focused strategy of AIxCrypto Holdings, Inc.

Market Impact and Investor Sentiment

The investor profile for Qualigen Therapeutics, Inc. (QLGN) has undergone a radical, near-term transformation, shifting sentiment from cautious to aggressively positive following a major strategic pivot. You need to stop thinking of QLGN as a biotech stock; it's now an AI and Web3 play, and the market is defintely reacting to the new majority owner.

The most crucial factor is the emergence of Faraday Future Intelligent Electric Inc. (FFAI) as the controlling shareholder. This is no passive investment; FFAI is taking the reins with an estimated direct equity ownership of 55%, which climbs to approximately 63% when including affiliated stockholders like YT Jia and Jerry Wang. This level of control, approved by stockholders in November 2025, signals a complete, top-down commitment to the new direction-a massive vote of confidence.

Institutional ownership, while historically low at around 3.18% of the stock, is now watching this shift closely. Even established names like BlackRock, Inc. and UBS Group AG, which hold positions, are now tied to a company that is rebranding to AIxCrypto Holdings, Inc. on November 20, 2025. This is a high-risk, high-reward bet, but the market loves a clean break from a struggling past.

Recent Market Reactions to the Strategic Pivot

The stock market's response to the new capital and strategic shift has been explosive and volatile. When the pivot to the AI x Web3 strategy and the $41 million PIPE financing led by Faraday Future were announced, the stock price surged by 211.97% on a single day in September 2025. This is the kind of move you see when a company fundamentally changes its business model.

More recently, the stock has shown a strong short-term uptrend, rising by 22.05% in the two weeks leading up to November 19, 2025, with the price sitting at $3.21 per share. This market activity shows investors are buying into the narrative, not the old financials. For a deeper dive into the former biotech's financial health, you can check out Breaking Down Qualigen Therapeutics, Inc. (QLGN) Financial Health: Key Insights for Investors.

Here's the quick math on the price action:

• Stock Price (Nov 14, 2025): $2.73
• Stock Price (Nov 19, 2025): $3.21
• Two-Week Gain (approx.): 22.05%

The market is pricing in the future, not the past. That's the key takeaway.

Analyst Perspectives on the New Majority Investor

Analysts are overwhelmingly optimistic about the stock's future, directly correlating the positive outlook with the Faraday Future investment and the new AIxCrypto strategy. The consensus is that the new controlling investor provides the capital and strategic direction necessary to execute this dramatic pivot, bypassing the old biotech risks.

The near-term price targets are staggering. The average analyst price target for the next 30 days is $25.02, which represents a potential increase of +679.43% from the November 19 price of $3.21. The average price forecast for the full year 2025 is $21.45. This optimism exists despite the company's recent losses.

What this estimate hides, of course, is the current financial reality you're investing away from. For the full year 2025, the forecasted annual Earnings Before Interest and Taxes (EBIT) is a loss of -$31 million. Also, the Q2 2025 earnings reported a loss of -$1.7 million. The analyst perspective is essentially saying the new strategic value from the key investor and the AI/Web3 pivot completely overshadows the legacy business's negative cash flow.

The technical analysis sentiment is also highly favorable, with 20 bullish signals outweighing 6 bearish signals as of November 18, 2025. The market is betting on the new management team and the new business model, plain and simple.